Anna Karlsson

Anna Karlsson

Auto-generated profile, based on publicly available information

Anna Karlsson

Division of Oncology, Department of Clinical Sciences Lund, Lund University, Medicon Village, Lund, Sweden

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
JLJanne Lehtiö
Janne Lehtiö
TATaner Arslan
Taner Arslan
ISIoannis Siavelis
Ioannis Siavelis
YPYanbo Pan
Yanbo Pan
FSFabio Socciarelli
Fabio Socciarelli
LOLukas M. Orre
Lukas M. Orre

30 July 2012 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
KHKatja Harbst
Katja Harbst
JSJohan Staaf
Johan Staaf
MLMartin Lauss
Martin Lauss
AKAnna Karlsson
Anna Karlsson
AMAnna Måsbäck
Anna Måsbäck
Göran JönssonGöran Jönsson
Göran Jönsson
Purpose: For primary melanomas, tumor thickness, mitotic rate, and ulceration are well-laid cornerstones of prognostication. However, a molecular exposition of melanoma aggressiveness is critically missing. We recently uncovered a four-class structure in metastatic melanoma, which predicts outcome and informs biology. This raises the possibility that a molecular structure exists even in the early stages of melanoma and that molecular determinants could underlie histophenotype and eventual patient outcome. Experimental Design: We subjected 223 archival primary melanomas to a horizontally integrated analysis of RNA expression, oncogenic mutations at 238 lesions, histomorphometry, and survival data. Results: Our previously described four-class structure that was elucidated in metastatic lesions was evident within the expression space of primary melanomas. Because these subclasses converged into two larger prognostic and phenotypic groups, we used the metastatic lesions to develop a binary subtype-based signature capable of distinguishing between “high” and “low” grade forms of the disease. The two-grade signature was subsequently applied to the primary melanomas. Compared with low-grade tumors, high-grade primary melanomas were significantly associated with increased tumor thickness, mitotic rate, ulceration (all P < 0.01), and poorer relapse-free (HR = 4.94; 95% CI, 2.84–8.59), and overall (HR = 3.66; 95% CI, 2.40–5.58) survival. High-grade melanomas exhibited elevated levels of proliferation and BRCA1/DNA damage signaling genes, whereas low-grade lesions harbored higher expression of immune genes. Importantly, the molecular-grade signature was validated in two external gene expression data sets. Conclusions: We provide evidence for a molecular organization within melanomas, which is preserved across all stages of disease. Clin Cancer Res; 18(15); 4026–36. ©2012 AACR.

28 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MAMattias Aine
Mattias Aine
DNDeborah F. Nacer
Deborah F. Nacer
EAElsa Arbajian
Elsa Arbajian
SVSrinivas Veerla
Srinivas Veerla
AKAnna Karlsson
Anna Karlsson
JSJohan Staaf
Johan Staaf
Triple-negative breast cancer (TNBC) is a clinically challenging and molecularly heterogenous breast cancer subgroup. Here, we investigate the DNA methylation landscape of TNBC. By analyzing tumor methylome profiles and accounting for the genomic context of CpG methylation, we divide TNBC into two epigenetic subtypes corresponding to a Basal and a non-Basal group, in which characteristic transcriptional patterns are correlated with DNA methylation of distal regulatory elements and epigenetic regulation of key steroid response genes and developmental transcription factors. Further subdivision of the Basal and non-Basal subtypes identifies subgroups transcending genetic and proposed TNBC mRNA subtypes, demonstrating widely differing immunological microenvironments, putative epigenetically-mediated immune evasion strategies, and a specific metabolic gene network in older patients that may be epigenetically regulated. Our study attempts to target the epigenetic backbone of TNBC, an approach that may inform future studies regarding tumor origins and the role of the microenvironment in shaping the cancer epigenome.

20 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JSJohan Staaf
Johan Staaf
DEDaniel Ehinger
Daniel Ehinger
Hans BrunnströmHans Brunnström
Hans Brunnström
MJMats Jönsson
Mats Jönsson
FRFrida Rosengren
Frida Rosengren
EAElsa Arbajian
Elsa Arbajian
Background: Squamous cell lung carcinoma (SqCC) is the second most common histological subtype of lung cancer. Besides -tumor-initiating and promoting DNA, RNA, and epigenetic alterations, aberrant tumor cell metabolism has been identified as one of the hallmarks of carcinogenesis. The aim of the current study was to identify SqCC-specific metabolites and key gene regulators that could eventually be used as new anticancer targets. Methods: Transcriptional (n=156), proteomics (n=118), and mass spectrometry-based metabolomic data (n=73) were gathered for a cohort of resected early-stage lung cancers representing all major histological subgroups. SqCC-specific differentially expressed genes were integrated with proteogenomic and metabolic data using genome scale metabolic models (GEMs). Findings were validated in cohorts of tumors, normal specimens, and cancer cell lines. In situ protein expression of SLC6A8 was investigated in 213 tumors. Results: Differential gene expression analysis identified 280 SqCC-specific genes, of which 57 were connected to metabolites through GEMs. Metabolic profiling identified 7 SqCC-specific metabolites, of which increased creatine and decreased phosphocholine levels matched to SqCC-specific elevated expression of SLC6A8 and decreased expression of CHKA, part of respective GEMs. Expression of both genes appeared tumor cell-associated, and in particular the elevated expression of SLC6A8 identified SqCC also in stage IV disease. Conclusion: Elevated creatine levels and the overexpression of its transporter protein SLC6A8 appear as a distinct metabolic feature of SqCC. Considering ongoing clinical trials focused on SLC6A8 inhibition in other malignancies, exploring SLC6A8 inhibition in SqCC appears motivated based on a metabolic addiction hypothesis.